RAPGEF3 and atherosclerosis: These findings suggest that the strong predictive value of EPAC1 in identifying advanced plaque burden in patients may stem from the profound impact of hypoxia—a key driver of atherosclerosis progression [23–25]—on EPAC1 production by foam-hcVSMCs.